Tryg A/S
Transactions in connection with share buyback programme
Transactions in connection with share buyback programme
On 04 December 2024, Tryg A/S (“Tryg”) announced that the Board of Directors had decided to initiate a share buyback programme of up to DKK 2.0 billion. The share buyback programme is executed in accordance with EU Market Abuse Regulation, EU Regulation no. 596/2014 of 16 April 2014 and the provisions of Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the “Safe Harbour Regulation”). The share buyback programme will end no later than 30 June 2025.
Transactions made under the share buyback programme will be announced through Nasdaq Copenhagen on a weekly basis.
The following transactions have been executed in the period 14 April 2025 to 16 April 2025:
| | Number of shares | Avg. purchase price, DKK | Transaction value, DKK |
| 14 April 2025 | 90,000 | 149.84 | 13,485,600 |
| 15 April 2025 | 80,000 | 151.88 | 12,150,400 |
| 16 April 2025 | 80,000 | 150.85 | 12,068,000 |
| Accumulated for the period | 250,000 | | 37,704,000 |
| Accumulated under the programme | 10,276,787 | | 1,568,072,334 |
Detailed information on all transactions under the share buyback programme during the period is included in the attached appendix.
Following the above transactions, Tryg owns a total of 10,771,472 treasury shares corresponding to 1.748% of the total share capital.
Contact information:
- Gianandrea Roberti, SVP Head of Investor Relations +45 20 18 82 67, gianandrea.roberti@tryg.dk
- Robin Hjelgaard Løfgren, Head of Investor Relations, +45 41 86 25 88, robin.loefgren@tryg.dk
- Peter Brondt, Investor Relations Director +45 22 75 89 04, peter.brondt@tryg.dk
Visit tryg.com
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Vivoryon Therapeutics N.V.13.5.2025 07:00:00 CEST | Press release
Vivoryon Therapeutics N.V. to Hold its 2025 Annual General Meeting on June 24, 2025
Kuros Biosciences AG13.5.2025 07:00:00 CEST | Press release
Kuros Biosciences to share latest MagnetOs™ market impact and strategic priorities at Capital Market Day in Zürich
dsm-firmenich13.5.2025 07:00:00 CEST | Press release
Weekly progress on share repurchase program to cover share plans and reduce capital
NMD Pharma13.5.2025 07:00:00 CEST | Press release
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA International Conference on Myasthenia and Relate
F. Hoffmann-La Roche Ltd13.5.2025 07:00:00 CEST | Press release
Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom